RPS6 and neoplasm: Immunohistochemically, the tumor revealed a weak-to-moderate expression of phosphorylated mTOR (protein phosphorylation site SER2884, Cell Signaling Technology, Danvers, MA, USA) and a strong expression of the two main target proteins of the mTOR complex 1, namely, phosphorylated eukaryotic translation initiation factor 4E binding protein 1 (p-4EBP1; Clone 53H11, Cell Signaling Technology) and phosphorylated ribosomal p‐RPS6 (protein phosphorylation site SER235/236, Cell Signaling Technology; Fig. 1d–f).